OBJECTIVES: In Egypt, B-thalassemia creates financial burden on the patients’ family and the society. Iron overload is a common clinical problem, arising from long-term transfusion therapy which is required to improve life expectancy for B-thalassemia patients. Iron chelation therapy is often used to remove excess stored iron and to reverse related complications including hepatic, endocrinological and cardiac dysfunction. The aim of this study was to perform a cost minimization analysis (CMA) of generic versus brand form of Deferasirox in the management of B-thalassaemia patients with chronic iron overload from the health care provider perspective. METHODS: Direct medical costs were reported in Egyptian pounds of the financial year 2016. The doses were calculated for an average patient weight of 30.5 kg. Discounting was needed as costs were calculated for a time horizon of 20 years. One way sensitivity analysis was conducted and all the variables were varied with a range of ±10%. RESULTS: Total costs for generic and brand form of Deferasirox were EGP 19,454,775 and EGP 29,038,688, respectively. This study revealed that the generic form of Deferasirox is the least expensive drug when compared to it'seems brand form in the management of B-thalassaemia patients with chronic iron overload from the health care provider perspective. One way sensitivity analysis showed that the costs of drugs have the highest impact on the results. CONCLUSIONS: The generic form of dferasirox is the preferred drug compared to its brand form in the management of B-thalassaemia patients with chronic iron overload from the health care provider perspective.